Dario Tuccinardi

Prof. Dario Tuccinardi

Campus Bio-Medico di Roma
+1

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2021 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PDF file
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
ABAngela Balena
Angela Balena
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
RTRossella Tozzi
Rossella Tozzi
RRRenata Risi
Renata Risi
LGLucio Gnessi
Lucio Gnessi
Aims: To explore variables associated with the serological response following COVID‐19 mRNA vaccine.Methods: Eighty‐six healthcare workers adhering to the vaccination campaign against COVID‐19 were enrolled in January–February 2021. All subjects underwent two COVID‐19 mRNA vaccine inoculations (Pfizer/BioNTech) separated by 3 weeks. Blood samples were collected before the 1st and 1–4 weeks after the second inoculation. Clinical history, demographics, and vaccine side effects were recorded. Baseline anthropometric parameters were measured, and body composition was performed through dual‐energy‐X‐ray absorptiometry.Results: Higher waist circumference was associated with lower antibody (Ab) titres (R = −0.324, p = 0.004); smokers had lower levels compared to non‐smokers [1099 (1350) vs. 1921 (1375), p = 0.007], as well as hypertensive versus normotensive [650 ± 1192 vs. 1911 (1364), p = 0.001] and dyslipideamic compared to those with normal serum lipids [534 (972) vs 1872 (1406), p = 0.005]. Multivariate analysis showed that higher waist circumference, smoking, hypertension, and longer time elapsed since second vaccine inoculation were associated with lower Ab titres, independent of BMI, age. and gender.Conclusions: Central obesity, hypertension, and smoking are associated with lower Ab titres following COVID‐19 vaccination. Although it is currently impossible to determine whether lower SARS‐CoV‐2 Abs lead to higher likelihood of developing COVID‐19, it is well‐established that neutralizing antibodies correlate with protection against several viruses including SARS‐CoV‐2. Our findings, therefore, call for a vigilant approach, as subjects with central obesity, hypertension, and smoking could benefit from earlier vaccine boosters or different vaccine schedules.

APAndrea Palermo
Andrea Palermo
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
Giuseppe DefeudisGiuseppe Defeudis
Giuseppe Defeudis
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
LDLuca D'Onofrio
Luca D'Onofrio
SMSilvia Manfrini
Silvia Manfrini
Recent evidence demonstrating an increased fracture risk among obese individuals suggests that adipose tissue may negatively impact bone health, challenging the traditional paradigm of fat mass playing a protective role towards bone health. White adipose tissue, far from being a mere energy depot, is a dynamic tissue actively implicated in metabolic reactions, and in fact secretes several hormones called adipokines and inflammatory factors that may in turn promote bone resorption. More specifically, Visceral Adipose Tissue (VAT) may potentially prove detrimental. It is widely acknowledged that obesity is positively associated to many chronic disorders such as metabolic syndrome, dyslipidemia and type 2 diabetes, conditions that could themselves affect bone health. Although aging is largely known to decrease bone strength, little is yet known on the mechanisms via which obesity and its comorbidities may contribute to such damage. Given the exponentially growing obesity rate in recent years and the increased life expectancy of western countries it appears of utmost importance to timely focus on this topic.

1 October 2020 in Metabolism
Verified
Journal Article
Closed access
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
Damiano CarusoDamiano Caruso
Damiano Caruso
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
RRRenata Risi
Renata Risi
MZMarta Zerunian
Marta Zerunian
LGLucio Gnessi
Lucio Gnessi

27 January 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
ABAdriano Bruci
Adriano Bruci
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
RTRossella Tozzi
Rossella Tozzi
ABAngela Balena
Angela Balena
SSSilvia Santucci
Silvia Santucci
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
Very low-calorie ketogenic diets (VLCKD) are an effective and increasingly used tool for weight loss. Traditionally considered high protein, ketogenic diets are often looked at with concern by clinicians due to the potential harm they pose to kidney function. We herein evaluated the efficacy and safety of a VLCKD in patients with obesity and mild kidney failure. A prospective observational real-life study was conducted on ninety-two patients following a VLCKD for approximately 3 months. Thirty-eight had mild kidney failure and fifty-four had no renal condition and were therefore designated as control. Anthropometric parameters, bioelectrical impedance and biochemistry data were collected before and at the end of the dietary intervention. The average weight loss was nearly 20% of initial weight, with a significant reduction in fat mass. We report an improvement of metabolic parameters and no clinically relevant variation regarding liver and kidney function. Upon stratification based on kidney function, no differences in the efficacy and safety outcomes were found. Interestingly, 27.7% of patients with mild renal failure reported normalization of glomerular filtrate after dietary intervention. We conclude that, when conducted under the supervision of healthcare professionals, a VLCKD is an effective and safe treatment for weight loss in patients with obesity, including those affected by mild kidney failure.

9 August 2018 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
ANAnnunziata Nusca
Annunziata Nusca
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
MAMarzia Albano
Marzia Albano
CCCamilla Cavallaro
Camilla Cavallaro
ERElisabetta Ricottini
Elisabetta Ricottini
GSGermano Di Sciascio
Germano Di Sciascio

1 May 2017 in Metabolism
Verified
Journal Article
Closed access
APAndrea Palermo
Andrea Palermo
Dario TuccinardiDario Tuccinardi
Dario Tuccinardi
LDLuca D'Onofrio
Luca D'Onofrio
Mikiko WatanabeMikiko Watanabe
Mikiko Watanabe
DMDaria Maggi
Daria Maggi
SMSilvia Manfrini
Silvia Manfrini